RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Phase 3RecruitingNCT05758831

Rennes University Hospital386 enrolled

Overview

The goal of this randomized clinical trial is to compare relapse remitting multiple sclerosis (RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on the % of patients without disease activity at 2 years. During the 2 years, the study includes 6 follow-up visits and the completion of various health and quality of life questionnaires. The protocol visits follow the usual schedule of treatment infusions for the disease (at initiation of treatment, 15 days after, and then every 6 months). Two comparison groups: Researchers will compare rituximab treated patients versus ocrelizumab treated patients to see the % of patients without disease activity at 2 years.

Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous system (CNS). This disease is the leading cause of non-traumatic disability in young adults and France is characterized by a high prevalence (currently 1/1000 inhabitants) of MS. Clinical trials with B cell depleting therapies have shown efficacy in relapsing-remitting MS (RRMS) and are increasingly perceived as an important addition to the existing panel of Disease-modifying treatments (DMTs). Rituximab, a mouse chimeric anti CD20, is approved for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, certain forms of vasculitis and Rheumatoid Arthritis with first marketing approval in 1998. Rituximab has undergone clinical testing in RRMS in 2008 in a phase II placebo-controlled trial, demonstrating the clinico-radiological efficacy in 104 patients. Despite these promising results and the absence of adverse events, its clinical development was interrupted by the manufacturer (Roche). However, for several years, rituximab has been increasingly prescribed (off-label) in Europe and USA in patients refractory to first-line therapies, with a very good safety and efficacy. Thus, rituximab is prescribed for 40% of RRMS patients treated in Sweden. Roche has then developed a humanized anti-CD20 monoclonal antibody (Ocrelizumab). Two phase III clinical trials (OPERA I and II) have demonstrated its efficacy in active RRMS. Ocrelizumab has just been authorized in France in this indication: RRMS patients with active disease (clinical or radiological). So, it can be prescribed as a first line or second line therapy in active RRMS patients. According to literature, there are no biological arguments to think that ocrelizumab could be more effective in active RRMS compared to rituximab. Moreover, regarding safety, rituximab has been used for other indications for almost two decades and no serious concern has arisen. The high cost of this new antibody (x6 to 10) compared to rituximab) makes it wonder about its place inside the anti-CD20 therapeutic strategy compared to rituximab for treating relapsing MS patients. Hypothesis: Researchers hypothesize that rituximab and ocrelizumab have the same efficacy in active RRMS patients. Indeed, if the non-inferiority of rituximab on the % of patients without disease activity is confirmed by the trial, the potential medico-economic benefit from a societal perspective will be a strong argument to ask for authorization of rituximab in active RRMS.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients presenting a relapsing remitting MS according to Mac Donald 2017 criteria, with clinical or radiological criteria of activity (ie at least one relapse AND/OR one new T2 lesion in the last 12 months before inclusion); * Age between 18 and 55 years * EDSS ≤ 5 * Brain MRI within 6 months before inclusion * For women of childbearing potential\*: effective contraception (effective contraception include oral contraception, intrauterine devices and other forms of contraception with failure rate \<1%, for the duration of the study and until 12 months after last dose administered) \* A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. * Having signed an informed consent form * Patients covered with social insurance Non-Inclusion Criteria: * Secondary or primary progressive MS; * Previous treatment by mitoxantrone, cladribine, alemtuzumab and anti CD20 therapies in the last two years; * Previous treatment by fingolimod or natalizumab in the last 4 weeks; * Treatment with high dose corticosteroids during the 30 days preceding the inclusion; * Occurrence of a relapse less than 30 days before inclusion; * Pregnancy or breastfeeding; * Other neurologic or systemic disease; * Concomitant participation or Participation in another therapeutic trial in the last 6 months; * Incapacity to understand or sign the consent form; * Contraindication to MRI; * Contraindication to anti-CD20 therapies: * Receipt of a live or live-attenuated vaccine within 6 weeks prior to randomization * Active malignancy. * Any ongoing infection * Severe heart failure (New York Heart Association Class IV) or severe uncontrolled cardiac disease * Positive test for HIV, hepatitis B or C, or tuberculosis * Severe immune deficiency: * Lymphopenia grade 3 (0.2 to 0.5 × 10\^9/L) or higher grades * Neutropenia grade 3 (0.5 to 1.0 × 10\^9/L) or higher grades * Known hypersensitivity or other known side effects for any of the study medications, including co-medications such as high glucocorticosteroids * AST or ALT \>=3ULN * Platelet (thrombocyte) count \< 100 x 10\^9/L * Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.

Locations (23)

Hospices Civils de Lyon Hôpital Neurologique Pierre Wertheimer

Lyon, Bron, France

NOT_YET_RECRUITING

CHRU de Brest - Hôpital la Cavale Blanche

Brest, France

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Caen

Caen, France

RECRUITING

Centre Hospitalier de Pontoise - GHT NOVO

Cergy-Pontoise, France

NOT_YET_RECRUITING

Hôpital Gabriel Montpieds

Clermont-Ferrand, France

NOT_YET_RECRUITING

Centre hospitalier de Gonnesse

Gonesse, France

NOT_YET_RECRUITING

Groupe Hospitalier de l'Institut Catholique de Lille

Lille, France

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Limoges

Limoges, France

NOT_YET_RECRUITING

AP-HM - Hôpital la Timone

Marseille, France

RECRUITING

CHRU de Montpellier - Hôpital Gui de Chauliac

Montpellier, France

RECRUITING

...and 13 more locations

Outcomes

Primary Outcomes

To demonstrate the non-inferiority of rituximab versus ocrelizumab in active relapsing MS patients on the percentage of patients without disease activity at 2 years.

Percentage of patients without disease activity at 2 years (Disease activity is defined as: * At least one relapse between baseline and M24 * OR MRI activity defined as Gd enhancing lesions at M6 or as the appearance of at least one new T2 lesion between M6 and M24)

Time frame: at 2 years

Secondary Outcomes

To compare the two groups (ocrelizumab vs rituximab) for Clinical Criteria : o Annualized relapse rate

Relapses: annualized relapse rate

Time frame: at 2 years

To compare the two groups (ocrelizumab vs rituximab) for Clinical Criteria : o Time of onset of the first relapse

mean time of onset of the first relapse

Time frame: at 2 years

To compare the two groups (ocrelizumab vs rituximab) for Clinical Criteria : o Percentage of patients without relapse

Percentage of patients without relapse

Time frame: at 2 years

To compare the two groups (ocrelizumab vs rituximab) for Clinical Criteria : o Percentage of patients without disability progression

Percentage of patients without disability progression (Expanded Disability Status Scale-EDSS) (Disability progression will be defined as an increase of 1.5 pt if baseline EDSS=0, 1pt EDSS (if baseline 1 ≤ EDSS\<6), or an increase of 0.5pt if baseline EDSS is ≥ 6; confirmed at 6 months.) EDSS : Minimum Score 1, Maximum score 10, higher scores mean a worse outcome.

Time frame: at 2 years

MRI parameters : gadolinium (Gd) enhancing lesions

\- Mean number of Gd enhancing lesions at M6

Time frame: at 6 month

MRI parameters : gadolinium (Gd) enhancing lesions

\- Percentage of patients with at least one Gd enhancing lesion(s)

Time frame: at 6 month

MRI parameters : Mean Number of new T2 lesions

\- Mean number of new brain T2 lesions

Time frame: From Month 6 to Month 24

MRI parameters : Percentage of patients with one or more new T2 lesions

\- Percentage of patients with one or more new brain T2 lesions

Time frame: From Month 6 to Month 24

Patients quality of life : EQ-5D-5L

Change in the EQ-5D-5L score The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.

Time frame: From baseline (Day 0) to every six month of follow up until Month 24

Patients quality of life : MusiQOL (Multiple Sclerosis International Quality of Life questionnaire)

Change in the MusiQOL score The MusiQoL is a specific questionnaire comprising 31 questions describing nine dimensions of quality of life (Appendix 1): activities of daily living (eight items); psychological well-being (four); relationships with friends (four); symptoms (three); relationships with family (three); relationships with the health care system (three); emotional and sexual life (two); coping (two); rejection (two). Each item is scored from 1 (never/not at all) to 5 (always/very much). Before calculating the score of the dimensions, the scores of negatively written items are reversed. The score of a dimension is obtained by averaging the scores of its constituent items. The dimension scores are then transformed linearly into scores ranging from 0 to 100 (100 being the maximum quality of life level). A global quality of life score is also available.

Time frame: From baseline (Day 0) to Month 12

Patients quality of life : MusiQOL

Time frame: From baseline (Day 0) to Month 24

Patients experience : Musicare

Change in the Musicare score Musicare is a questionnaire to assess the experience of both patients and caregivers of quality of care in MS, in accordance with psychometric standards. It comprises 35 items encompassing 5 domains: Information about the disease (11), Information about the treatments/medical investigation (8), Relationships with health care teams (8) Health care access (5) Reception in care structures (3). Each item is scored from 1 (Strongly agree) to 5 (Don't know).

Time frame: From baseline (Day 0) to Month 12

Patients experience : Musicare

Time frame: From baseline (Day 0) to Month 24

Medico-economic impact: cost-utility ratio, QALY

Incremental Cost-Effectiveness Ratio (ICER) defined as the cost for QALY gained in "ocrelizumab group" versus "rituximab group" at 24 months.

Time frame: At 2 years

Safety: Number of each adverse event

Number of each adverse event will be compared between the two groups

Time frame: At 2 years

Safety: Number of each severe adverse events

Number of each severe adverse events will be compared between the two groups

Time frame: At 2 years

RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

Overview

Conditions

Interventions

Eligibility

Locations (23)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts